📣 VC round data is live. Check it out!
- Public Comps
- Etropal
Etropal Valuation Multiples
Discover revenue and EBITDA valuation multiples for Etropal and similar public comparables like Balsm Alofoq, iZafe Group, Jin Medical International, Airway Medix and more.
Etropal Overview
About Etropal
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
Founded
1976
HQ

Employees
168
Website
Sectors
Financials (FY)
EV
$14M
Valuation Multiples
Start free trialEtropal Financials
Etropal reported last fiscal year revenue of $10M and EBITDA of $748K.
In the same fiscal year, Etropal generated $3M in gross profit, $748K in EBITDA, and $54K in net income.
Etropal P&L
In the most recent fiscal year, Etropal reported revenue of $10M and EBITDA of $748K.
Etropal is profitable as of last fiscal year, with gross margin of 30%, EBITDA margin of 8%, and net margin of 1%.
Financial data powered by Morningstar, Inc.
Etropal Stock Performance
Etropal has current market cap of $14M, and enterprise value of $14M.
Market Cap Evolution
Etropal's stock price is $2.71.
Etropal share price increased by 0.9% in the last 30 days, and decreased by 45.3% in the last year.
Etropal has an EPS (earnings per share) of $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14M | $14M | 0.5% | 0.9% | -0.1% | -45.3% | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEtropal Valuation Multiples
Etropal trades at 1.4x EV/Revenue multiple, and 18.1x EV/EBITDA.
Etropal Financial Valuation Multiples
As of May 10, 2026, Etropal has market cap of $14M and EV of $14M.
Etropal has a P/E ratio of 252.5x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Etropal Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Etropal Margins & Growth Rates
In the most recent fiscal year, Etropal reported gross margin of 30%, EBITDA margin of 8%, and net margin of 1%.
Etropal Margins
Etropal Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Etropal Operational KPIs
Etropal's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Etropal Competitors
Etropal competitors include Balsm Alofoq, iZafe Group, Jin Medical International, Airway Medix, Ortivus, BioRegenx, Farmaceutica Remedia, Prolight Diagnostics, BPC Instruments and Cuprina Holdings (Cayman).
Most Etropal public comparables operate across Medical Supplies.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.4x | — | 12.9x | — | |||
| 23.2x | — | (11.6x) | — | |||
| 0.3x | — | 6.1x | — | |||
| 11675.6x | — | 13.4x | — | |||
| 2.4x | — | (11.9x) | — | |||
| 5.9x | — | (9.3x) | — | |||
| 0.0x | — | 1.4x | — | |||
| — | — | (2.6x) | — | |||
This data is available for Pro users. Sign up to see all Etropal competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Etropal
| When was Etropal founded? | Etropal was founded in 1976. |
| Where is Etropal headquartered? | Etropal is headquartered in Bulgaria. |
| How many employees does Etropal have? | As of today, Etropal has over 168 employees. |
| Is Etropal publicly listed? | Yes, Etropal is a public company listed on Bulgarian Stock Exchange. |
| What is the stock symbol of Etropal? | Etropal trades under ETR ticker. |
| When did Etropal go public? | Etropal went public in 2007. |
| Who are competitors of Etropal? | Etropal main competitors include Balsm Alofoq, iZafe Group, Jin Medical International, Airway Medix, Ortivus, BioRegenx, Farmaceutica Remedia, Prolight Diagnostics, BPC Instruments, Cuprina Holdings (Cayman). |
| What is the current market cap of Etropal? | Etropal's current market cap is $14M. |
| What is the current revenue of Etropal? | Etropal's last fiscal year revenue is $10M. |
| What is the current EV/Revenue multiple of Etropal? | Current revenue multiple of Etropal is 1.4x. |
| Is Etropal profitable? | No, Etropal is not profitable. |
| How many companies Etropal has acquired to date? | Etropal hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Etropal has invested to date? | Etropal hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Etropal
Lists including Etropal
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.